| Identification | Back Directory | [Name]
GYPENOSIDE-XVII | [CAS]
80321-69-3 | [Synonyms]
GP-17
Gypenoside ⅩⅦ
Gynosaponin S
GYPENOSIDE-XVII
Gypenoside XVII (Gynosaponin S)
3β-(β-D-Glucopyranosyloxy)-12β-hydroxy-5α-dammar-24-en-20-yl 6-O-β-D-glucopyranosyl-β-D-glucopyranoside
β-D-Glucopyranoside, (3β,12β)-3-(β-D-glucopyranosyloxy)-12-hydroxydammar-24-en-20-yl 6-O-β-D-glucopyranosyl-
(3beta,12beta)-3-(beta-D-Glucopyranosyloxy)-12-hydroxydammar-24-en-20-yl 6-O-beta-D-glucopyranosyl-beta-D-glucopyranoside | [Molecular Formula]
C48H82O18 | [MDL Number]
MFCD10566703 | [MOL File]
80321-69-3.mol | [Molecular Weight]
947.15 |
| Chemical Properties | Back Directory | [Melting point ]
>183°C (dec.) | [Boiling point ]
1013.5±65.0 °C(Predicted) | [density ]
1.38 | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly), Pyridine (Slightly) | [form ]
Solid | [pka]
12.90±0.70(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Gypenoside XVII is a major saponin abundant in ginseng and Panax notoginseng which ameliorated amyloid-(Aβ)25-35-induced apoptosis in PC12 cells by regulating autophagy. | [Definition]
ChEBI: Gypenoside XVII is a ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 3 and 20 have been converted to the corresponding beta-D-glucopyranoside and beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite. It is a 12beta-hydroxy steroid, a beta-D-glucoside, a disaccharide derivative, a ginsenoside and a tetracyclic triterpenoid. It derives from a hydride of a dammarane. | [in vivo]
Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE-/- mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE-/- model group[1]. |
|
|